NMR* based Lipoprotein Phenotyping reveals severity and recovery subgroups in populations infected by SARS-CoV-2
NMR* based Lipoprotein Phenotyping reveals severity and recovery subgroups in populations infected by SARS-CoV-2

NMR* based Lipoprotein Phenotyping reveals severity and recovery subgroups in populations infected by SARS-CoV-2

Webinar Overview

Members of the NMR International COVID-19 Research Network have published grounding breaking research showing how NMR spectroscopy has played a key role in our growing understanding of the long-term systemic effects of SARS-CoV-2 infection, using metabolic phenotyping. Listen to Prof. Julien Wist as he is discussing about how NMR can contribute.


Speaker Abstract

Abstract written by Professor Julien Wist (Professor of Computational Spectroscopy at the ANPC)

The biological processes behind the response of patients to infection by SARS-CoV-2 are not fully understood. Applying a broad phenotypic approach on a longitudinal cohort enabled the identification of key markers associated with 1) the onset of the acute phase (phenoconversion) and posterior normalisation process (phenoreversion), 2) the risk of death and 3) the risk of developing post-acute covid syndrome – PACS or long-COVID. The phenotypic profiles included clinical, immune and inflammation parameters along with glycoproteins, lipoproteins, and other small molecular weight metabolites. The cohort was carefully stratified according to the severity of the respiratory symptoms.

Our results indicate that regardless of respiratory symptoms and their severity a disturbance to the metabolic signature could be observed. Moreover, 3 sub-phenotypes (mildly affected; severely affected but recovering; not recovering) could be identified at the onset of the disease that relate with both the respiratory severity and the prospect of recovery. Other metabolic markers which were perturbed could be linked to brain metabolism and associated to patients experiencing neurological symptoms 6 months post infection.  Similarly, markers for cardiovascular risks were elevated in acute patients, a warning of future complications that certainly explains the excess cardiovascular risk burden observed in population infected by SARS-CoV-2.

Interestingly, a high degree of covariance was found between standard clinical parameters such as CRP and parameters from the distinct panels, meaning that surrogate markers could be used. Indeed, lipoprotein and glycoprotein parameters are accurate predictors of the disease outcome and of cardiovascular risk. These parameters are readily obtained from NMR experiments acquired in <10 minutes, with minimal and non-destructive sample preparation. With an ongoing pandemic and a large portion of the world population already affected, it is timely to expand our testing capability to monitoring the recovery (phenoreversion).

Who Should Attend?

NMR* scientists

Researchers studying COVID 19 disease

Clinical trial investigators



* Bruker NMR Instruments are for Research Use Only. Not for Use in Clinical Diagnostic Procedures


Professor Julien Wist

Professor Wist is Professor of Computational Spectroscopy at the ANPC. In addition to the establishment of new mathematical and statistical paradigms, Professor Wist will lead the construction of organised data architectures for storage, retrieval, processing and visualization, and the implementation of novel pipelines unique to metabolic phenotyping.


Input value is invalid.

Are you already in contact with your Bruker representative regarding any product inquiries?

We constantly want to improve our service for our customers. In answering the following question you help us to serve your needs even better in the future: What best describes your situation?

By ticking this box, I agree to receive, from time to time, emails from Bruker and its affiliates within the Bruker Group on upcoming events, webinars, our products and services, surveys and Bruker's corporate news.
I can unsubscribe at any time, by contacting Bruker or clicking on the opt-out link in the email if available. For more information on the processing of your personal data, please check Bruker’s Privacy Policy. 

By submitting this form I agree my personal data will be used to process my registration to the webinar. I have read and accepted the Bruker Website Privacy Notice (https://www.bruker.com/privacy-policy.html) and I agree to the Terms of Use (https://www.bruker.com/terms-of-use.html) of the Bruker website.

Already registered and lost your invitation link?

Thank you. The invitation link has been resent.